Rochester, Minn.-based Mayo Clinic researchers analyzed data from 22,000 clinical trial participants, following those with and without low ejection fraction. They simulated the long-term progression of low ejection fraction, assigning values for health burden and economic effect, according to a Dec. 4 news release from Mayo Clinic.
“We categorized patients as either AI-ECG positive, meaning we would recommend further testing for low ejection fraction, or AI-ECG negative with no further tests needed. Then we followed the normal path of care and looked at what that would cost,” Xiaoxi Yao, PhD, professor of health services research at Mayo Clinic and senior author of the study, said in the release.
The use of AI-powered ECG also resulted in a $1,651 cost-effectiveness ratio per quality-adjusted life year in outpatient settings.
Read the full study here.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
